Merck & Co. June pipeline wins draw valuation focus, shares near mid-range NYSE levels

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-23, 13:04.

Merck & Co. (US58933Y1055) faces renewed valuation scrutiny this week as investors digest several June pipeline milestones while the shares trade around 115 US dollars on the NYSE. According to TrendSpider price data, Merck shares last closed at about 115.47 dollars on 22 June 2026.

What recent reports highlight

An analysis from Simply Wall St points to Merck stock potentially trading about 11 percent below an estimated fair value of 129.74 dollars after a cluster of June pipeline wins, including new U.S. FDA approvals for cancer therapy KEYTRUDA and kidney cancer drug WELIREG, plus pneumococcal vaccine CAPVAXIVE. The same piece notes successful Phase 3 data for ulcerative colitis candidate tulisokibart, adding to the company’s late-stage pipeline momentum.

A separate German-language overview on ad-hoc-news.de summarizes the current consensus picture: data providers such as MarketBeat and MarketScreener list a majority of Buy and Outperform recommendations on Merck with average price targets above the last NYSE closing level. That report also reiterates that Merck shares most recently changed hands at about 115.47 dollars at the close of NYSE trading on 22 June 2026, keeping the stock in the middle of its recently observed trading range.

Analyst views and valuation context

MarketBeat’s aggregation, cited in the ad-hoc-news.de summary, shows that a clear majority of covering analysts currently rate Merck at Buy or equivalent, with only a minority on Hold and very few Sell views. MarketScreener’s data set, referenced in the same article, indicates that the average 12-month price target sits meaningfully above the roughly 115 dollar spot level, signaling upside potential in the consensus models.

Simply Wall St’s fair-value approach suggests a theoretical value of 129.74 dollars per share based on discounted cash-flow assumptions, implying that the stock could be around 11 percent undervalued relative to the latest close. However, the analysis also emphasizes that execution on the late-stage pipeline, including potential commercial uptake of new KEYTRUDA indications and CAPVAXIVE, will be critical to realize that value.

The medicines behind Merck’s revenue

Merck generates a substantial share of its revenue from oncology immunotherapy KEYTRUDA (pembrolizumab), which is approved in a broad range of cancer indications worldwide. Additional important growth drivers include human papillomavirus vaccine GARDASIL/GARDASIL 9, cardiometabolic products and a growing vaccines portfolio that now features the pneumococcal vaccine CAPVAXIVE in the United States.

Where the shares trade now

Merck & Co. shares (US58933Y1055) most recently closed on the NYSE at 115.47 US dollars as of 2026-06-22, 21:59, according to TrendSpider data referenced by ad-hoc-news.de.

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. Investors should conduct their own research and consider their individual financial situation before making investment decisions.